Real-world evidence on health-related quality of life in patients with type 2 diabetes mellitus using sulphonylureas: An analysis of the Joint Asia Diabetes Evaluation (JADE) Register
Issued Date
2023-09-01
Resource Type
ISSN
01688227
eISSN
18728227
Scopus ID
2-s2.0-85168517488
Pubmed ID
37517776
Journal Title
Diabetes Research and Clinical Practice
Volume
203
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes Research and Clinical Practice Vol.203 (2023)
Suggested Citation
Lim L.L., S. H. Lau E., Pheng Chan S., Ji L., Lim S., Sirinvaravong S., Unnikrishnan A.G., O. Y. Luk A., Cortese V., Durocher A., C. N. Chan J. Real-world evidence on health-related quality of life in patients with type 2 diabetes mellitus using sulphonylureas: An analysis of the Joint Asia Diabetes Evaluation (JADE) Register. Diabetes Research and Clinical Practice Vol.203 (2023). doi:10.1016/j.diabres.2023.110855 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/89588
Title
Real-world evidence on health-related quality of life in patients with type 2 diabetes mellitus using sulphonylureas: An analysis of the Joint Asia Diabetes Evaluation (JADE) Register
Other Contributor(s)
Abstract
Aims: To describe health-related quality of life (HRQoL) and identify associated factors in patients with type 2 diabetes mellitus (T2DM) treated with oral glucose-lowering drugs (OGLDs). Methods: This retrospective, cross-sectional analysis included adults with T2DM from 11 Asian countries/regions prospectively enrolled in the Joint Asian Diabetes Evaluation (JADE) Register (2007–2019) with available EuroQol-5D (EQ-5D-3L) data. Results: Of 47,895 included patients, 42,813 were treated with OGLDs + lifestyle modifications (LSM) and 5,082 with LSM only. Among those treated with OGLDs, 60% received sulphonylureas (SUs), of whom 47% received gliclazide. The OGLD + LSM group had a lower mean EQ-5D-3L index score than the LSM-only group (p < 0.001). The most affected EQ-5D-3L dimensions in OGLD + LSM-treated patients were pain/discomfort (26.2%) and anxiety/depression (22.6%). On multivariate analysis, good HRQoL was positively associated with male sex, education level, balanced diet and regular exercise, and negatively with complications/comorbidities, self-reported hypoglycaemia, smoking, HbA1c, age, body mass index and disease duration. Patients receiving gliclazide vs non-gliclazide SUs had lower HbA1c and better HRQoL in all dimensions (p < 0.001). Conclusions: Demographic, physical and psychosocial-behavioural factors were associated with HRQoL in patients with T2DM. Our real-world data add to previous evidence that gliclazide is an effective OGLD, with most treated patients reporting good HRQoL. A plain language summary of this manuscript is available here.